Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

Cédric Mercier, Laetitia Dahan, L'Houcine Ouafik, Nicolas André, Joseph Ciccolini

► To cite this version:

Cédric Mercier, Laetitia Dahan, L'Houcine Ouafik, Nicolas André, Joseph Ciccolini. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. *European Journal of Clinical Pharmacology*, 2010, 66 (9), pp.959-960. 10.1007/s00228-010-0859-5 . hal-00601561

HAL Id: hal-00601561

<https://hal.science/hal-00601561>

Submitted on 19 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Letter to the Editor : Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2010-0152
Type of submission:	Letter
Date Submitted by the Author:	20-Apr-2010
Complete List of Authors:	Mercier, Cedric; La Timone University Hosiptal, Medical Oncology Dahan, Laetitia; La Timone University Hospital, Digestive Oncology Ouafik, L'Houcine; North University Hospital, Transfer Oncology Laboratory André, Nicolas; La Timone university Hospital, Paediatric Oncology Ciccolini, joseph; North University Hospital of Marseille, Transfer Oncology Laboratory

Letter to the Editor : Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

Cédric Mercier, Laetitia Dahan, L'Houcine Ouafik, Nicolas André, Joseph Ciccolini

C. Mercier : Medical Oncology Unit, La Timone University Hospital of Marseille, France.

L. Dahan: Digestive Oncology, La Timone University Hospital of Marseille, France.

L. Ouafik: Transfer Oncology Laboratory, North University Hospital of Marseille, France.

N. André, Paediatric Oncology Unit, La Timone University Hospital of Marseille, France.

J. Ciccolini (✉): Transfer Oncology Laboratory, North University Hospital of Marseille, 13015 Marseille France. Email: joseph.ciccolini@univmed.fr

Keywords: pharmacogenetics, gemcitabine, pharmacokinetics

Dear Sir,

We have read with great interest the article entitled “Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism” by Maring J et al. which has been recently published in the European Journal of Clinical Pharmacology [1]. We would like to comment on the article by referring to our own non-clinical and clinical studies on evaluating the relationships between CDA status (either determined from a phenotypic or a genotypic basis) and pharmacokinetics or clinical outcome in individuals treated with gemcitabine [2]. Maring et al. studied the impact of the canonical 79A>C polymorphism in the cytidine deaminase (CDA) gene on the pharmacokinetics of gemcitabine and its main inactive metabolite 2',2'-difluorodeoxyuridine (dFdU) in non-small-cell lung cancer (NSCLC) patients. They conclude, from this genotypic-based study, that this polymorphism has little impact on gemcitabine pharmacokinetics eventually. Of note, in this study, CDA status was never evaluated using a functional test, and no clinical data (e.g., relationships between allelic variants and the incidence of severe toxicities) were made available to further confirm the little relevance 79A>C polymorphism had on clinical outcome with gemcitabine. However, as fairly underlined by the authors, several experimental or clinical reports have previously evidenced the importance of the 79A>C mutation, both in term of impact on CDA activity, or as a biomarker predictive of toxicity/response with gemcitabine at the bedside [3-5]. In their paper, Maring et al. list a variety of possible confounding factors explaining this discrepancy, such as epigenetic deregulations, dose levels, sample size or lack of treatment uniformity in the patients they enrolled. In the light of our own expertise on genetic polymorphism affecting CDA and subsequently patients undergoing gemcitabine-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

based therapies, we do believe that the absence of impact of the 79A>C Maring et al. have evidenced is not artifactual. Actually, we reached the same conclusion in a pilot study performed in animals as well as in 150 patients (130 adults, 20 children) designed to evaluated whether CDA genetic polymorphism was a culprit for early severe toxicities upon gemcitabine intake [2]. In our study, we proved that CDA deficiency led to marked alterations of the gemcitabine pharmacokinetics profile in animals, with subsequent unrecoverable haematological toxicities. In patients, the 79A>C mutation was screened along with the 208G>A and 435T>C polymorphisms, and failed to be correlated with either CDA activity or clinical outcome. Conversely, sorting the same patients next on a CDA phenotypic status, rather than on a genotypic one, was fully predictive of those undergoing drug-induced severe toxicities, regardless of the dose administered, or the associated treatments. In this respect, the recent study by Maring et al. is of interest, because it fully supports the hypothesis that the gemcitabine pharmacogenetics issue should be better addressed using functional tools, rather than with a candidate gene approach. Finally, we would like to emphasize that the apparently negative conclusions of this paper should not deter physicians from moving toward a more personalized medicine with gemcitabine, since it all depends on the tools you use to custom treatment.

References

1. Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, Uges DR, de Vries EG, Groen HJ. (2010) Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol. Mar 6. [Epub ahead of print]

2. Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C. (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. *J Clin Oncol.* 28:160-5.
3. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J (1998) Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. *Exp Hematol* 26:421-425.
4. Gilbert JA et al (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. *Clin Cancer Res* 12:1794-1803
5. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan A, Nannizzi S et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced nonsmal cell lung cancer patients. *Clin Cancer Res* 14:1797-1803.